80 results
15F-12B
CLYYF
Celyad Oncology SA
9 Feb 24
Securities registration termination (foreign)
6:07am
residents, Celyad has relied on CMI2I Ltd., an independent information services provider.
Item 6. Debt Securities
Not applicable.
Item 7. Notice
6-K
EX-99.2
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
independent lump sums to the Walloon Region (mainly relating toC-Cathez
agreements).
As documented in the notes 2.5.6 and 2.5.8, Management had
6-K
EX-10.1
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
herein.
7.10 Severability. The provisions of this Agreement are independent of and separable from each other. The invalidity, illegality
6-K
EX-10.4
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
-speaking enterprise court of Brussels.
Section 5.6 Severability. The provisions of this Agreement are independent of and separable from each other
6-K
EX-10.2
CLYYF
Celyad Oncology SA
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
by the independent registered public accountants who have certified the Company’s financial statements included in such registration statement (and, if necessary, any … other independent registered public accountant of any Subsidiary of the Company or any business acquired by the Company from which financial
6-K
EX-99.1
r1ly38gi
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.3
xm1edj gndc
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-99.1
0omxmgk0msshyb2
15 May 23
Celyad Oncology announces receipt of Nasdaq delisting notice
7:21pm
6-K
2abi32rwbh
15 May 23
Celyad Oncology announces receipt of Nasdaq delisting notice
7:21pm
6-K
EX-99.1
h91m mkvzi1
5 May 23
Celyad Oncology Announces Intent to
7:21am
6-K
EX-99.1
805vnd b1dy
10 Nov 22
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
4:14pm
6-K
EX-99.2
2q00lyes 84
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.1
1uf5lvqz wzqwz
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.1
ylw aowkl8
24 Mar 22
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
5:45pm
6-K
EX-99.1
f8y gil9t
12 Jan 22
Celyad Oncology Provides Outlook for 2022
6:06am
6-K
EX-99.2
yifjvry
13 Dec 21
Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition
4:19pm